Comparative Pharmacology
Head-to-head clinical analysis: LYRICA CR versus VIGADRONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LYRICA CR versus VIGADRONE.
LYRICA CR vs VIGADRONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing calcium influx and inhibiting excitatory neurotransmitter release (e.g., glutamate, norepinephrine, substance P).
Irreversible inhibitor of GABA transaminase (GABA-T), leading to increased brain concentrations of gamma-aminobutyric acid (GABA).
Initial 75 mg orally twice daily (150 mg/day), or 50 mg three times daily (150 mg/day). Based on efficacy and tolerability, may increase to 150 mg twice daily (300 mg/day) after 1 week, then to 225 mg twice daily (450 mg/day) if needed. Maximum dose 450 mg/day. Take with food. Administer whole; do not split, crush, or chew.
Adults: 500 mg orally twice daily, may increase by 500 mg/day every week; maximum 1500 mg twice daily.
None Documented
None Documented
6.3 hours (mean terminal elimination half-life); correlates with creatinine clearance, prolonged in renal impairment.
Terminal elimination half-life: 5-7 hours in young adults; 12-15 hours in elderly; therapeutic steady-state achieved within 2-3 days.
Primarily renal excretion as unchanged drug (98-99% of absorbed dose); <0.1% biliary/fecal.
Renal: 70% unchanged; hepatic metabolism: 20% (primarily via CYP4A7, not CYP450); fecal: <5%.
Category C
Category C
Anticonvulsant
Anticonvulsant